Portrazza (necitumumab)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Portrazza (necitumumab)

How to buy Portrazza:  You can order Portrazza (necitumumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Eli Lilly and Co.
Disease Lung Cancer
Indication Squamous Non-Small Cell Lung Cancer
Mode of Action Epidermal Growth Factor (EGFR) Antagonist (immunotherapy)
Approval Status EMA approved (EU); FDA approved (USA)
Strength 16 mg/mL

Who is necitumumab for?

Necitumumab is indicated in combination with gemcitabine and cisplatin — two widely approved medicines — for the treatment of patients with metastatic squamous non-small cell lung cancer [1][2].

Recommended dose

Complete information about necitumumab’s dosage and administration can be found here: [1][3].
The standard dosage is:
  • 800 mg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle [1][3]
  • Administered in addition to gemcitabine and cisplatin-based chemotherapy for up to 6 cycles of treatment followed by necitumumab as a single agent in patients whose disease has not progressed, until disease progression or unacceptable toxicity [3]
  • Administer necitumumab prior to gemcitabine and cisplatin infusion [1].
Consult your treating doctor for personalised dosing.

What is necitumumab and how does it work?

Necitumumab is a monoclonal antibody used to treat adults with metastatic squamous non-small cell lung cancer [2].
The active substance in Portrazza, necitumumab, is an epidermal growth factor receptor (EGFR) antagonist [1], a type of protein designed to recognise and attach to EGFR on the surface of the cancer cells. EGFR normally controls the growth and division of cells, but in cancer cells EGFR is often overactive, causing the cells to divide uncontrollably. By attaching to and blocking EGFR, necitumumab helps to reduce the growth and spread of the cancer [2].

What is necitumumab's approval status?

Necitumumab was approved by:
  • FDA (USA) on November 11, 2015 [4]
  • EMA (EU) on March 4, 2016 [2]
for the treatment of adults with advanced squamous NSCLC.
The approvals were based on a study (SQUIRE) involving 1,093 patients with advanced squamous non-small cell lung cancer who received the chemotherapies gemcitabine and cisplatin with or without Portrazza (necitumumab). Patients treated with necitumumab in addition to chemotherapy lived on average 1.6 months longer than those treated with chemotherapy alone (11.5 months (95% CI 10.4, 12.6) versus 9.9 months (95% CI 8.9, 11.1))[3][1]. The 1-year overall survival rate was 47.7 % with necitumumab and 42.8% without [3]. The median progression free survival (PFS) was 5.7 months (95% CI 5.6, 6.0) when necitumumab was added to the therapy and 5.5 months (95% CI 4.8, 5.6) without necitumumab's addition [3][1].
Necitumumab was not found to be an effective treatment in patients with non-squamous NSCLC [2][4].
The most common side effects of Portrazza are skin rash and magnesium deficiency (hypomagnesemia), which can cause muscular weakness, seizure, irregular heartbeats and can be fatal. Necitumumab’s serious risks include cardiac arrest and sudden death, as well as hypomagnesemia [4].
References
[1] Summary of Product Characteristics [FDA]: Portrazza (necitumumab), Eli Lilly and Co., Nov. 2015.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
[2] EMA. Human Medicines: Portrazza (necitumumab), 04/03/2016 (last update: 05/12/2016), cited on 15/03/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003886/human_med_001953.jsp&mid=WC0b01ac058001d124
[3] Summary of Product Characteristics [EMA]: Portrazza (necitumumab), Eli Lilly Nederland B.V., Dec. 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003886/WC500202694.pdf
[4] FDA News Release: FDA approves Portrazza to treat advanced squamous non-small cell lung cancer, 24/11/2015.
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474131.htm

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.